Abstract: In general, the patent herein is a radioactive chemical which attaches to the virus and releases radiation which kills the virus. Specifically, the chemical is an alpha-ketoamide designed to attach to the virus. However, instead of 2 bromine atoms, Iodine-131 is at the location of where the bromine atoms would have been. Iodine-131 is a radioactive element which releases ionizing radiation. The virus with which this radioactive chemical is designed for is the COVID-19 coronavirus, although the patent is for any virus. Since, modifications can be made in chemical structure and radioactive chemical species, the patent is for any and all chemicals which contain any type of radioactive element to kill or disrupt any type of virus.

Abstract: A system for the rapid development of vaccines or anti-bacterial drugs is required when working with pandemics. The easiest way to formulate these new vaccines is through computational reduction of existing organisms via statistical models. Once vaccine candidates are arrived at through this method, “Super Organisms” containing all of the computationally reducible fragments can then be taken through a Crispr reduction process wherein those computationally reducible fragments are removed. The result is a vaccine candidate which has possible problematic function partially or fully removed. The “neutered” version of the virus can be tested in a lab and in clinical trials for efficacy. This patent covers a vaccine candidate utilizing computationally reducible fragments 100 base pairs or greater in length; those fragments removed from future Covid-19 Super Organisms either collectively (as in this patent) or individually; as well as the RNA transcripts of those fragments.

Abstract: A system for the rapid development of vaccines or anti-bacterial drugs is required when working with pandemics. The easiest way to formulate these new vaccines is through computational reduction of existing organisms via statistical models. Once vaccine candidates are arrived at through this method, “Super Organisms” containing all of the computationally reducible fragments can then be taken through a Crispr reduction process wherein those computationally reducible fragments are removed. The result is a vaccine candidate which has possible problematic function partially or fully removed. The “neutered” version of the virus can be tested in a lab and in clinical trials for efficacy. This patent covers a vaccine candidate utilizing computationally reducible fragments 75 to 99 base pairs in length; those fragments removed from future Covid-19 Super Organisms either collectively (as in this patent) or individually; as well as the RNA transcripts of those fragments.

Abstract: A system for the rapid development of vaccines or anti-bacterial drugs is required when working with pandemics. The easiest way to formulate these new vaccines is through computational reduction of existing organisms via statistical models. Once vaccine candidates are arrived at through this method, “Super Organisms” containing all of the computationally reducible fragments can then be taken through a Crispr reduction process wherein those computationally reducible fragments are removed. The result is a vaccine candidate which has possible problematic function partially or fully removed. The “neutered” version of the virus can be tested in a lab and in clinical trials for efficacy. This patent covers a vaccine candidate utilizing computationally reducible fragments related to Civet SARS, Bat Sars, and BtRs and BtRI BetaCov; those fragments removed from future Covid-19 Super Organisms either collectively (as in this patent) or individually; as well as the RNA transcripts of those fragments.

Abstract: Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods can be used to reduce the severity of outcomes related to COVID-19, such as hospitalization and ventilation. For example, the methods can involve treatment of a subject with a therapeutic agent that degrades hyaluronan and/or an agent that neutralizes a hyaluronan receptor, e.g., CD44, such as an anti-CD44 antibody.

Abstract: The present invention provides methods, immunoglobulin compositions and vector constructs as a general approach to provide episomal based immune protection from the 2019 novel coronavirus (COVID-19), its variants/mutants and other pandemic and even non-pandemic viruses.

Abstract: An ATM inhibitor can be used in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.

Abstract: The present invention encompasses ATR inhibitor for use in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.

Abstract: The present invention encompasses ATR inhibitor for use in the treatment of virus infections, including SARS-CoV infections such as COVID-19, alone or in combination with one or more additional therapeutic agents.

Abstract: Methods of detecting SARS-CoV-2 antibodies with improved specificity are described. The methods can include contacting a sample potentially containing SARS-CoV-2 antibodies with a reagent to remove non-anti-SARS-CoV-2 antibodies, such as a reagent comprising an epitope from a nucleocapsid protein or spike protein of a common coronavirus. The methods can include contacting the sample with a mutant SARS-CoV-2 nucleocapsid protein or spike protein comprising a reduced number of common coronavirus epitopes. The methods can involve comparing results from an immunoassay performed with a SARS-CoV-2 protein to results obtained from immunoassays performed with analogous protein from one or more common coronaviruses.

Abstract: Assessment of pulmonary function in coronavirus patients includes use of a computer aided diagnostic system to assess pulmonary function and risk of mortality in patents with coronavirus disease 2019. The CAD system processes thoracic X-ray data from a patient, extracts imaging markers, and grades disease severity based at least in part on the extracted imaging markers, thereby distinguishing between higher risk and lower risk patients. An alternative approach is to use an automatic CAD system to grade COVID-19 from computed tomography (CT) images to determine an accurate diagnosis of lung function.

Abstract: The present patent consists of an engineered multimeric protein complex as antibody substitute composed of human proteins, with an m-fold symmetry, with each m-fold element containing a modified monomeric protein derived from a symmetric human multimeric protein complex fused to a module containing n fused, modified human beta solenoid proteins (mBSP), and that fused to a human derived pathogen binding domain (PBD), as well as a separate antibody substitute composed of P human PBD complexes. The invention may find application in prophylactic and therapeutic treatments for viral infections, especially for COVID19 by neutralizing the SARS-CoV-2 virus.

Abstract: This nonprovisional patent application discloses an innovative electrolytic chamber assembly and associated methods for generating on-demand hydrogen-oxygen gases. The assembly comprises a series of metal electrode plates, neutrals, and terminal assemblies meticulously designed for efficient hydrogen and oxygen gas production. The inventive design includes precise milling, spot welding, and sealing techniques to ensure optimal performance and prevent leaks. Furthermore, this application introduces the concept of a complete system utilizing the advanced electrolytic design details in this patent, variations in the power supply methods for the electrolytic chamber, and the integration of engine sensor signal capture and adjustment means, both manually and through software driven applications. The power supply methods address issues related to voltage, ampere, and frequency regulation and efficiency.

Abstract: This “in vivo” medical treatment/diagnostic invention has the “intended use” of bombarding the family of coronavirus cells (and COVID-19 and variants) with an energy beam at a tuned frequency to cause them to resonant at a turbulent velocity the outer shell shatters causing their destruction. A Treatment Probe is advanced through the mouth into the windpipe, then an energy beam of extremely high frequency electromagnetic waves causes the cells to react by oscillating at a turbulence sufficient to shatter their electrostatic viral fields thus denaturing these viral cells The remaining active cells are attack by the body's immune system. Repeating treatment sessions stimulate the body's immune system to denatures/destroys the family of coronavirus cells.

Abstract: The invention provides the use of a formulation containing cyclodextrine, quercetin and zinc at appropriate concentrations to mitigate infections by enveloped viruses, such as COVID-19 virus (SARS-CoV-2), influenza and HIV. While the different forms of cyclodextrin prevent the entry of coated viruses into host cells by extracting and sequestering cholesterol molecules at the virus envelope and at the host cell plasma membrane, the natural plant-based ionophore quercetin in the formulation enables cellular entry of zinc, inhibiting viral replication by altering polymerase activity in the host cell. SUBSTANCE: This formulation is adapted for both surface use and introduction to a subject by dispersal, utilizing the known methods of measured nasal sprays or inhalers, wet wipes and medicated masks. The formulation is introduced in the form of an aqueous phosphate buffered saline pH 7.5 solution, containing 0.